Human fibroblast interferon for clinical trials: production, partial purification, and characterization

Area of Science:

• Biotechnology
• Immunology
• Cell Biology

Background:

• Human fibroblast interferon is a crucial therapeutic agent.
• Large-scale production and purification are necessary for clinical applications.

Purpose of the Study:

• To describe the production and partial purification of human fibroblast interferon.
• To characterize the final product and identify contaminants for clinical trial readiness.

Main Methods:

• Interferon production via superinduction of human diploid fibroblast cultures.
• Purification using acid desorption from glass beads and polyethylene glycol dialysis.
• Compositional analysis via crossed immunoelectrophoresis.

Main Results:

• Interferon yield averaged 750 units/cm(2).
• Purified product achieved specific activity of 0.5-1 x 10(6) units/mg protein.
• Fibronectin identified as a key fibroblast-derived contaminant.

Conclusions:

• A scalable method for producing and purifying human fibroblast interferon was established.
• The purified interferon is suitable for clinical trials, with characterized purity and activity.
• Understanding contaminants like fibronectin is essential for safety and efficacy.